Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by Utah Retirement Systems

Utah Retirement Systems raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,800 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the quarter. Utah Retirement Systems’ holdings in Alnylam Pharmaceuticals were worth $1,100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. Airain ltd bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $1,141,000. Prudential Financial Inc. grew its position in Alnylam Pharmaceuticals by 4.8% in the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 200 shares in the last quarter. Victory Capital Management Inc. grew its position in Alnylam Pharmaceuticals by 4.9% in the second quarter. Victory Capital Management Inc. now owns 26,025 shares of the biopharmaceutical company’s stock worth $2,076,000 after acquiring an additional 1,210 shares in the last quarter. Federated Investors Inc. PA grew its position in Alnylam Pharmaceuticals by 522.9% in the second quarter. Federated Investors Inc. PA now owns 62,293 shares of the biopharmaceutical company’s stock worth $4,968,000 after acquiring an additional 52,293 shares in the last quarter. Finally, Tocqueville Asset Management L.P. grew its position in Alnylam Pharmaceuticals by 16.9% in the second quarter. Tocqueville Asset Management L.P. now owns 16,575 shares of the biopharmaceutical company’s stock worth $1,322,000 after acquiring an additional 2,400 shares in the last quarter. 94.27% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by Utah Retirement Systems” was published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/utah-retirement-systems-grows-stake-in-alnylam-pharmaceuticals-inc-alny/1601633.html.

A number of analysts have recently weighed in on ALNY shares. Cowen and Company reiterated a “buy” rating and set a $100.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Jefferies Group LLC set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Barclays PLC increased their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 10th. Credit Suisse Group increased their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 27th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $99.00 price target (down from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $82.25.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded down 1.78% on Friday, hitting $76.76. 226,378 shares of the stock traded hands. The company’s market cap is $7.04 billion. The stock has a 50 day moving average of $81.65 and a 200 day moving average of $68.34. Alnylam Pharmaceuticals, Inc. has a one year low of $31.38 and a one year high of $89.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company’s revenue was up 82.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.05) EPS. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.18) earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster


Leave a Reply

 
© 2006-2017 BBNS.